ncRNAs in Drug Metabolism and the Translation of Gene Silencing Technology into Therapeutics
Sunday April 07, 2019
8:00 am
-
10:00 am
Eastern Time (ET)
Room W206 C
CVP
DDD
DMDD
TOX
Chair :
Baitang Ning
Natl Ctr for Toxicological Research, FDA
Julie Lade
Amgen, Inc. USA
Piled evidence has demonstrated that non-coding RNAs (ncRNAs) play an important role in mediating the inter-individual variability observed in drug metabolism through the modulation of genes encoding drug metabolizing enzymes and transporters (DMETs) in addition to nuclear receptors. In contrast to the mechanism by which endogenous ncRNAs impact gene expression, synthetic interfering RNA (siRNA) has become rapidly under investigation as a therapeutic strategy to inhibit the translation of messenger RNA in an effort to treat human diseases. This symposium will provide a blended overview of recent research pertaining to ncRNAs and exogenous oligonucleotides within the context of drug metabolism and gene silencing, respectively.
Speakers
Dianke Yu
- School of Public Health, Qingdao University
Functional Characterization of ncRNAs in the Regulation of CYPs
Michael Court
- Washington State University, USA
Regulation of UGTs by MicroRNAs and Drug Toxicity
Faraz Kazmi
- Janssen Research & Development
Inhibition of Drug Metabolizing Enzymes and Drug Transporters by Phosphodiester- or Phosphorothioate-linked Oligonucleotides
Sara Humphreys
- PKDM, Amgen Inc.
siRNA-protein Interactions in the Context of siRNA-based Therapeutics
Hannah Petrek
- UC Davis
Bioengineering of Single ncRNA Molecule for Multi-Targeting Against NSCLC